Pathological Outcomes Associated With the 17q Prostate Cancer Risk Variants

Brian T. Helfand, Stacy Loeb, Joshua J. Meeks, Angela J. Fought, Donghui Kan, William J. Catalona*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Purpose: Recent studies have identified 2 distinct genetic variants along chromosome 17, including allele T of single nucleotide polymorphism rs4430796 on 17q12 and allele G of single nucleotide polymorphism rs1859962 on 17q24, that have been linked to prostate cancer risk. Less is known about tumor pathological features in carriers of these variants. Materials and Methods: Genotypes for regions 17q12 and 17q24 were determined in 759 white men with prostate cancer and compared to those in 790 healthy control volunteers using logistic regression. In patients with prostate cancer the Fisher exact or Kruskal-Wallis test was used as appropriate to assess the relationship(s) between clinical and pathological characteristics with 17q carrier status. Results: The frequency of the 17q12 and 17q24 genetic variants was significantly higher in patients with prostate cancer compared to that in controls (OR 1.32, 1.15, respectively). Of patients with prostate cancer 83% and 77% were carriers of the 17q12 and 17q24 variants as well as 75% and 75% of controls, respectively. Carriers of 17q12 risk variants were significantly more likely to have high grade disease using an additive best fit genetic model. In addition, there were trends toward adverse pathological features associated with 17q12 independent of the best fit genetic model. Conclusions: Sequence variants along 17q12 and 17q24 were present in a significantly higher proportion of our prostate cancer cases than in our controls. Adverse pathological features, including higher Gleason grade and pathological stage, were more frequent in 17q12 carriers. Since these alleles may act in conjunction with variants on other chromosomes to influence prostate cancer risk, additional research is required to determine the cumulative associations of genetic risk variants with prognosis.

Original languageEnglish (US)
Pages (from-to)2502-2507
Number of pages6
JournalJournal of Urology
Issue number6
StatePublished - Jun 2009


  • chromosomes
  • gene expression
  • human
  • pair 17
  • prostate
  • prostatic neoplasms
  • risk

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Pathological Outcomes Associated With the 17q Prostate Cancer Risk Variants'. Together they form a unique fingerprint.

Cite this